Assessment of IgRT in patients with MM
| . | Patients with ≥1 IgRT∗ . |
|---|---|
| n = 471 . | |
| Number of IgRTs administered | |
| Mean ± SD | 5.0 ± 13.0 |
| Median (IQR) | 2.0 (1.0-4.0) |
| Range | (1-198) |
| n (%) | |
| 1 | 214 (45.4) |
| 2 | 78 (16.6) |
| 3 | 45 (9.6) |
| 4 | 28 (5.9) |
| 5 | 23 (4.9) |
| 6 | 11 (2.3) |
| 7 | 9 (1.9) |
| ≥8 | 63 (13.4) |
| Patients with 1 IgRT, n (%) | 214 (45.4) |
| Time from MM diagnosis to IgRT initiation, mo | |
| Mean ± SD | 38.0 ± 31.4 |
| Median (IQR) | 32.2 (10.2-58.4) |
| Time from IgRT initiation to end of follow-up, mo | |
| Mean ± SD | 34.3 ± 32.5 |
| Median (IQR) | 23.5 (6.0-51.8) |
| Year of first IgRT, n (%) | |
| 2010-2015 | 21 (9.8) |
| 2016-2020 | 130 (60.7) |
| 2021-2023 | 63 (29.4) |
| Patients with ≥2 IgRTs, n (%) | 257 (54.6) |
| Time from MM diagnosis to IgRT initiation, mo | |
| Mean ± SD | 35.1 ± 31.7 |
| Median (IQR) | 24.5 (10.5-53.5) |
| Time from IgRT initiation to end of follow-up, mo | |
| Mean ± SD | 38.6 ± 27.5 |
| Median (IQR) | 30.7 (16.9-60.7) |
| Time from first IgRT to second IgRT, mo | |
| Mean ± SD | 6.2 ± 10.7 |
| Median (IQR) | 3.1 (0.9-6.5) |
| Year of first IgRT, n (%) | |
| 2010-2015 | 35 (13.6) |
| 2016-2020 | 141 (54.9) |
| 2021-2023 | 81 (31.5) |
| . | Patients with ≥1 IgRT∗ . |
|---|---|
| n = 471 . | |
| Number of IgRTs administered | |
| Mean ± SD | 5.0 ± 13.0 |
| Median (IQR) | 2.0 (1.0-4.0) |
| Range | (1-198) |
| n (%) | |
| 1 | 214 (45.4) |
| 2 | 78 (16.6) |
| 3 | 45 (9.6) |
| 4 | 28 (5.9) |
| 5 | 23 (4.9) |
| 6 | 11 (2.3) |
| 7 | 9 (1.9) |
| ≥8 | 63 (13.4) |
| Patients with 1 IgRT, n (%) | 214 (45.4) |
| Time from MM diagnosis to IgRT initiation, mo | |
| Mean ± SD | 38.0 ± 31.4 |
| Median (IQR) | 32.2 (10.2-58.4) |
| Time from IgRT initiation to end of follow-up, mo | |
| Mean ± SD | 34.3 ± 32.5 |
| Median (IQR) | 23.5 (6.0-51.8) |
| Year of first IgRT, n (%) | |
| 2010-2015 | 21 (9.8) |
| 2016-2020 | 130 (60.7) |
| 2021-2023 | 63 (29.4) |
| Patients with ≥2 IgRTs, n (%) | 257 (54.6) |
| Time from MM diagnosis to IgRT initiation, mo | |
| Mean ± SD | 35.1 ± 31.7 |
| Median (IQR) | 24.5 (10.5-53.5) |
| Time from IgRT initiation to end of follow-up, mo | |
| Mean ± SD | 38.6 ± 27.5 |
| Median (IQR) | 30.7 (16.9-60.7) |
| Time from first IgRT to second IgRT, mo | |
| Mean ± SD | 6.2 ± 10.7 |
| Median (IQR) | 3.1 (0.9-6.5) |
| Year of first IgRT, n (%) | |
| 2010-2015 | 35 (13.6) |
| 2016-2020 | 141 (54.9) |
| 2021-2023 | 81 (31.5) |
IgRT use was assessed during the follow-up period.